BGI Genomics shareholder adjusts pledges, completes share reduction

Shenzhen BGI Genomics Co., Ltd. announced that Shenzhen Shenghua Investment Enterprise, a shareholder holding over 5% of the company's stock, completed a series of share pledge adjustments. Shenghua Investment released 3.5 million shares, representing 11.80% of its total holdings and 0.84% of the company's total share capital. Concurrently, Shenghua Investment re-pledged 6.6 million shares, accounting for 22.25% of its holdings and 1.58% of the company's total share capital, for financing purposes. Following these transactions, Shenghua Investment’s cumulative pledged shares amount to 27.44 million shares, representing 92.50% of its total holdings and 6.56% of the company's total share capital. The company clarified that these pledge adjustments do not involve significant asset restructuring or performance compensation obligations.

In a related announcement, BGI Genomics confirmed that Shenghua Investment had completed its share reduction plan. Between September 4, 2025, and December 3, 2025, Shenghua Investment cumulatively reduced its holdings by 4,805,301 shares, representing 1.1487% of the company’s total share capital. The sales were conducted through centralized bidding and block trading, at an average price of CNY 52.54 per share. Following the completion of the reduction plan, Shenghua Investment's total holdings in BGI Genomics decreased from 34,470,455 shares (8.2403%) to 29,665,154 shares (7.0915%). The company assured that Shenghua Investment is not a controlling shareholder or actual controller, and these transactions will not affect the company's control structure or ongoing operations.